At MSToronto 2026, investigators applied machine learning to health records, retinal scans, and blood samples to flag ...
The professor of applied neuroimaging at the University of Edinburgh discusses emerging imaging, blood-based, and functional biomarkers for tracking cerebral small vessel disease progression and ...
Changes in health care use emerged 5 to 6 years before the first clinical manifestation of MS, with shifts in encounter ...
The 36-month CORE-VNS study findings showed sustained seizure reduction, improved quality of life, and reduced ...
The editor-in-chief of the Journal of the American Heart Association discusses what editors prioritize in research manuscripts, common submission mistakes, and strategies for improving publication ...
A phase 1 clinical trial published in 2026 evaluated BBM-P002, an investigational gene therapy for Parkinson disease. Which ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
The FDA has accepted the resubmitted new drug application (NDA) for troriluzole (Vyglxia; Biohaven) for the treatment of ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years ...
A pooled analysis of 4 randomized trials found that more time with blood pressure below 130 mmHg after intracerebral ...
Remibrutinib (Novartis), an oral Bruton tyrosine kinase (BTK) inhibitor, reduced annualized relapse rate (ARR) vs ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results